Greenwich Lifesciences Inc (GLSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) has a cash flow conversion efficiency ratio of -1.223x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.67 Million) by net assets ($2.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Greenwich Lifesciences Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Greenwich Lifesciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GLSI total liabilities for a breakdown of total debt and financial obligations.
Greenwich Lifesciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Greenwich Lifesciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Favite Inc
TW:3535
|
0.039x |
|
RoadMain T Co Ltd
SHG:603860
|
-0.024x |
|
Pengana Private Equity Trust
AU:PE1
|
0.006x |
|
Tianyu Ecology & Landscape Co
SHG:603717
|
0.089x |
|
Bank of Greece
AT:TELL
|
N/A |
|
Borosil Limited
NSE:BOROLTD
|
0.059x |
|
Orient Cement Limited
NSE:ORIENTCEM
|
-0.027x |
|
Campine
BR:CAMB
|
-0.162x |
Annual Cash Flow Conversion Efficiency for Greenwich Lifesciences Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Greenwich Lifesciences Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see GLSI company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.53 Million | $-7.27 Million | -2.868x | -196.58% |
| 2023-12-31 | $6.70 Million | $-6.48 Million | -0.967x | -106.07% |
| 2022-12-31 | $13.21 Million | $-6.20 Million | -0.469x | -193.35% |
| 2021-12-31 | $26.83 Million | $-4.29 Million | -0.160x | -283.31% |
| 2020-12-31 | $27.63 Million | $-1.15 Million | -0.042x | -119.21% |
| 2019-12-31 | $-1.35 Million | $-293.27K | 0.217x | +1811.88% |
| 2018-12-31 | $-10.12 Million | $-114.95K | 0.011x | -19.82% |
| 2017-12-31 | $-8.53 Million | $-120.85K | 0.014x | -- |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also de… Read more